Product | Mechanism | Ownership | Indication | Preclinical | Clinical Proof-of-Concept | Pivotal |
---|---|---|---|---|---|---|
HM43239 | Myeloid Kinome | Aptose WW | AML |
complete
AML
Preclinical Phase complete
|
in progress
Clinical Proof-of-Concept Phase in progress
|
not started
Pivotal Phase not started
|
Luxeptinib | Lymphoid Kinome | Aptose: WW Crystal Genomics: Korea |
CLL & NHL |
complete
CLL & NHL
Preclinical Phase complete
|
in progress
Clinical Proof-of-Concept Phase in progress
|
not started
Pivotal Phase not started
|
Luxeptinib | Myeloid Kinome | Aptose: WW Crystal Genomics: Korea |
AML & MDS |
complete
AML & MDS
Preclinical Phase complete
|
in progress
Clinical Proof-of-Concept Phase in progress
|
not started
Pivotal Phase not started
|
APTO-253 | MYC | Aptose: WW | AML & MDS |
complete
AML & MDS
Preclinical Phase complete
|
in progress
Clinical Proof-of-Concept Phase in progress
|
not started
Pivotal Phase not started
|
APL-581 | BRD4/JAK | Aptose and Ohm | Hematologic Cancers |
in progress
Hematologic Cancers
Preclinical Phase in progress
|
not started
Clinical Proof-of-Concept Phase not started
|
not started
Pivotal Phase not started
|
Luxeptinib is being developed for the treatment of patients with certain B-cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and certain non-Hodgkin’s lymphomas (NHL) who are resistant or intolerant to conventional treatments.
View CandidateLuxeptinib is also being developed for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML), including the emerging populations resistant to approved targeted therapies.
View CandidateHM43239 is being developed for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML).
View CandidateOur online library includes numerous publications, including presentations, posters, and other media that provide additional information on preclinical and clinical studies of our drug candidates.
View Posters & Presentations